HIV11: UK Study Finds HIV+ Women on Antiretroviral Therapy Have Higher Premature Birth Rate
- Details
- Category: HIV Treatment
- Published on Monday, 26 November 2012 00:00
- Written by Gus Cairns
A review of clinical records from Central Manchester University Hospitals has found more evidence of an increased rate of preterm delivery of babies born to HIV positive women who are taking antiretroviral therapy (ART), according to a study presented at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow this month. 
HIV11: Life Expectancy in Older People with HIV Could Exceed the Average - As Long As ART Keeps Working
- Details
- Category: HIV Treatment
- Published on Tuesday, 20 November 2012 00:00
- Written by Gus Cairns
The latest forecasts of life expectancy in people with HIV in the U.K., based on mortality data from the UK Collaborative HIV Cohort (UK CHIC) study, show that the average life expectancy of people on antiretroviral therapy (ART) with a CD4 count over 350 cells/mm3 is now very close to the national average, the 11th International Congress on Drug Therapy in HIV Infection in Glasgow heard last week. 
Coverage of 11th International Congress on Drug Therapy in HIV Infection
- Details
- Category: HIV Treatment
- Published on Saturday, 17 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 11th International Congress on Drug Therapy in HIV Infection (HIV11), November 11-15, 2012, Glasgow, Scotland.
Conference highlights include experimental antiretroviral drugs, ART strategies, manging side effects, HIV-related non-AIDS conditions, treatment as prevention and PrEP, HIV/HCV coinfection, and the search for a cure for HIV.
HIVandHepatitis.com HIV11 conference section
11/17/12
HIV11: Complera Combo Pill as Effective as Atripla for First HIV Treatment, but Better Tolerability
- Details
- Category: HIV Treatment
- Published on Tuesday, 20 November 2012 00:00
- Written by Liz Highleyman
The Complera (rilpivirine/tenofovir/emtricitabine) single-tablet regimen suppressed HIV as well as the Atripla (efavirenz/tenofovir/emtricitabine) combination pill in treatment-naive people, but led to fewer adverse events -- in particular neuropsychiatric side effects associated with efavirenz, according to a report at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) last week in Glasgow. 
HIV11: Infants Who Start Antiretrovirals Early Keep HIV Suppressed Despite Treatment Interruption
- Details
- Category: HIV Treatment
- Published on Friday, 16 November 2012 00:00
- Written by Liz Highleyman
Babies who started taking lopinavir-based antiretroviral therapy (ART) soon after they were diagnosed with HIV experienced good virological response that was sustained through 6 years, even after they stopped treatment, according to long-term data from the CHER study presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.
Web Design and Development by